Clario has announced a strategic partnership with AI-powered digital pathology solution provider PathAI to offer an integrated solution for enhancing the efficiency of gastrointestinal (GI) clinical trials.
The collaboration will provide a single-vendor offering for anatomical pathology services and advanced video endoscopy assessments.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The parties aim to introduce an end-to-end process for CROs and sponsors.
This process will encompass training, logistics, tissue processing, slide digitisation, image analysis and data transfers, all under the medical and scientific oversight of experts.
Furthermore, clinical trial sites are set to benefit from simplified workflows, which include improved training, reporting and document management.
Clario gastroenterology medical director Marcela Vieira said: “At Clario we have long been at the forefront of supporting GI clinical trials, and we are excited to augment our strengths with PathAI’s capabilities in the area of discovery and patient care.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“The combination of endoscopy and histopathology promises to unlock new avenues for clinical research, and we are proud to be in this leadership position with our partners at PathAI.”
Under the deal, Clario will offer its expertise in GI trials, having supported more than 130 studies with advanced imaging solutions such as endoscopy, MRI and ultrasound.
The company’s technologies and scientists are aids in lowering site burden and bolstering trial efficiency with AI-powered reading for ulcerative colitis (UC) and high-definition video endoscopy support.
PathAI will offer its network of expert GI pathologists and anatomical pathology services, focusing on streamlining the handling of specimens and histological assessments to the partnership.
Its AI-powered offerings are designed to enhance UC assessment, reduce variability in histological scoring and accelerate biomarker discovery.
PathAI Biopharma chief business officer and president Matt Grow said: “We are thrilled to partner with Clario to provide a cutting-edge solution for IBD [inflammatory bowel disease] clinical trials.
“Our collaboration will offer an integrated approach in histology and endoscopy for assessing therapeutic efficacy, accelerating biomarker discovery and therapy development in IBD.”
